Evidence map›Paper›PMID 36014414›Full record

ArticleMolecules (Basel, Switzerland)2022

Quantitative Proteomics Explore the Potential Targets and Action Mechanisms of Hydroxychloroquine.

Jingxiang Zhao, Zhiqiang Zhao, Wanting Hou, Yue Jiang, Guobin Liu, Xuelian Ren, Kun Liu, Hong Liu, Kaixian Chen, He Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jingxiang ZhaoSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Zhiqiang ZhaoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.ORCID 0000-0002-0704-6904
Wanting HouShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yue JiangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Guobin LiuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Xuelian RenShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Kun LiuSchool of Mechanical Engineering and Automation, Northeastern University, Shenyang 110819, China.ORCID 0000-0003-0542-1739
Hong LiuSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Kaixian ChenSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
He HuangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.ORCID 0000-0001-6998-8131
Chinese Academy of Sciences · CNChina Pharmaceutical University · CNNortheastern University · CN

Funding

National Natural Science Foundation of China 81973164Shanghai Municipal Science and Technology Major Project NA
6 · The paper itself

Abstract

Hydroxychloroquine (HCQ) is an autophagy inhibitor that has been used for the treatment of many diseases, such as malaria, rheumatoid arthritis, systemic lupus erythematosus, and cancer. Despite the therapeutic advances in these diseases, the underlying mechanisms have not been well determined and hinder the rational use of this drug in the future. Here, we explored the possible mechanisms and identified the potential binding targets of HCQ by performing quantitative proteomics and thermal proteome profiling on MIA PaCa-2 cells. This study revealed that HCQ may exert its functions by targeting some autophagy-related proteins such as ribosyldihydronicotinamide dehydrogenase (NQO2) and transport protein Sec23A (SEC23A), or regulating the expression of galectin-8 (LGALS8), mitogen-activated protein kinase 8 (MAPK8), and so on. Furthermore, HCQ may prevent the progression of pancreatic cancer by regulating the expression of nesprin-2 (SYNE2), protein-S-isoprenylcysteine O-methyltransferase (ICMT), and cotranscriptional regulator FAM172A (FAM172A). Together, these findings not only identified potential binding targets for HCQ but also revealed the non-canonical mechanisms of HCQ that may contribute to pancreatic cancer treatment.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidLupus Erythematosus, SystemicPancreatic NeoplasmsGalectinsHumansHydroxychloroquineProteinsProteomicsAntirheumatic AgentsARB2A protein, humanGalectinsHydroxychloroquineLGALS8 protein, humanProteinshydroxychloroquinequantitative proteomicsthermal proteome profiling

Identifiers

PMID36014414
PMCPMC9416215
OpenAlexW4291891621

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.